ArticlePLoS pathogens2012
A novel mouse model of Schistosoma haematobium egg-induced immunopathology.
Article in PLoS pathogens, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 2 syntheses or guidelines pooled it, 111 citations in OpenAlex.
- Association of female genital schistosomiasis and human papillomavirus and cervical pre-cancer: a systematic review.BMC women's health · 2025Pooled it
- Effects of Schistosoma haematobium infection and treatment on the systemic and mucosal immune phenotype, gene expression and microbiome: A systematic review.PLoS neglected tropical diseases · 2024Pooled it
- Cervicovaginal Immune Activation in Zambian Women With Female Genital Schistosomiasis.Frontiers in immunology · 2021Trial
- IL-17A and IFN-α associated with female genital schistosomiasis lesions.BMC immunology · 2026Article
- Sex differences in bladder cancer: understanding biological and clinical implications.Biology of sex differences · 2025Review
- RNA-seq gene expression profiling of the bladder in a mouse model of urogenital schistosomiasis.bioRxiv : the preprint server for biology · 2024Article
- The abundance and morphology of human large intestinal goblet and tuft cells during chronic schistosomiasis.Parasite immunology · 2023Article
- T cell subsets, regulatory T, regulatory B cells and proinflammatory cytokine profile in Schistosoma haematobium associated bladder cancer: First report from Upper Egypt.PLoS neglected tropical diseases · 2023Article
- Article
- Protein undernutrition reduces the efficacy of praziquantel in a murine model of Schistosoma mansoni infection.PLoS neglected tropical diseases · 2022Article
- Dynamics in Morbidity Markers and Cytological Observations Made in Urine ofMedical sciences (Basel, Switzerland) · 2022Article
- Chromosome-level genome of Schistosoma haematobium underpins genome-wide explorations of molecular variation.PLoS pathogens · 2022Article
- Host tissue proteomics reveal insights into the molecular basis of Schistosoma haematobium-induced bladder pathology.PLoS neglected tropical diseases · 2022Article
- Programmed Cell Death-Ligand-1 expression in Bladder Schistosomal Squamous Cell Carcinoma -Frontiers in immunology · 2022Review
- The role of helminths in the development of non-communicable diseases.Frontiers in immunology · 2022Review
- Parasitic helminth infections in humans modulate Trefoil Factor levels in a manner dependent on the species of parasite and age of the host.PLoS neglected tropical diseases · 2021Article
- Urogenital Schistosomiasis-History, Pathogenesis, and Bladder Cancer.Journal of clinical medicine · 2021Review
- Schistosomiasis Morbidity Hotspots: Roles of the Human Host, the Parasite and Their Interface in the Development of Severe Morbidity.Frontiers in immunology · 2021Review
- Control Strategies for Carcinogenic-Associated Helminthiases: An Integrated Overview.Frontiers in cellular and infection microbiology · 2021Review
- Urinary schistosomiasis and the associated bladder cancer: update.Journal of the Egyptian National Cancer Institute · 2020Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Schistosoma haematobium is the etiologic agent for urogenital schistosomiasis, a major source of morbidity and mortality for more than 112 million people worldwide. Infection with S. haematobium results in a variety of immunopathologic sequelae caused by parasite oviposition within the urinary tract, which drives inflammation, hematuria, fibrosis, bladder dysfunction, and increased susceptibility to urothelial carcinoma. While humans readily develop urogenital schistosomiasis, the lack of an experimentally-tractable model has greatly impaired our understanding of the mechanisms that underlie this important disease. We have developed an improved mouse model of S. haematobium urinary tract infection that recapitulates several aspects of human urogenital schistosomiasis. Following microinjection of purified S. haematobium eggs into the bladder wall, mice consistently develop macrophage-rich granulomata that persist for at least 3 months and pass eggs in their urine. Importantly, egg-injected mice also develop urinary tract fibrosis, bladder dysfunction, and various urothelial changes morphologically reminiscent of human urogenital schistosomiasis. As expected, S. haematobium egg-induced immune responses in the immediate microenvironment, draining lymph nodes, and systemic circulation are associated with a Type 2-dominant inflammatory response, characterized by high levels of interleukin-4, eosinophils, and IgE. Taken together, our novel mouse model may help facilitate a better understanding of the unique pathophysiological mechanisms of epithelial dysfunction, tissue fibrosis, and oncogenesis associated with urogenital schistosomiasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.